Hexagon Nutrition IPO opens for subscription on June 5, 2026, and will remain open until June 9, 2026. The company plans to list its shares on both BSE and NSE with a tentative listing date of June 12, 2026. The IPO is priced in the band of ₹42 to ₹45 per share and aims to raise approximately ₹138.87 crore from investors. According to reports from ET Now, this marks the first mainboard public issue in June following a quiet market period. As per EQMint analysis, the nutrition and healthcare segment remains one of the fastest-growing consumer categories in India, making this a potentially attractive opportunity for retail investors.
The IPO has shown strong investor interest with total subscription reaching 2.19x by June 2, 2026, according to latest market data. The subscription breakdown shows retail investors subscribing 1.22x, non-institutional investors at 1.17x, and qualified institutional buyers at 1.2x. The anchor investor portion of 30% (92.58 lakh shares) was subscribed at 15.94x, indicating strong institutional confidence. The basis of allotment is scheduled for June 11, 2026, with refunds to be initiated on the same date. The company's pre-issue promoter holding stands at 89%, with the remaining shares being offered to public investors.
The IPO consists of a fresh issue component of ₹27.29 crore and an offer for sale of up to 3,08,59,704 equity shares. Retail investors can apply with a minimum bid of 333 shares worth ₹14,985 at the upper price band of ₹45 per share. The maximum retail application is capped at 13 lots comprising 4,329 shares amounting to ₹194,805. Small HNI investors require a minimum application of 14 lots or 4,662 shares worth ₹2,09,790, while Big HNI investors can apply from a minimum of 67 lots, which equals 22,311 shares and requires an investment of ₹10,03,995. According to EQMint analysis, the relatively affordable price band and mainboard listing structure could attract strong retail participation if grey market sentiment improves closer to listing.
According to the company's financial data, Hexagon has delivered consistent growth over the last three fiscal years, with revenue climbing from ₹281.65 crores in FY23 to ₹331.29 crores in FY25. The company's net profit nearly doubled between FY24 and FY25, with the nine-month period ending December 2025 showing continued momentum, with PAT already surpassing the full FY25 figure. Key financial metrics for FY25 include ROE of 10.47%, ROCE of 17.06%, EBITDA Margin of 12.33%, and PAT Margin of 7.36%. The company maintains a low debt-to-equity ratio of 0.14, indicating a conservatively leveraged balance sheet.
As reported by ET Now, Hexagon operates three manufacturing facilities in India (at Nasik, Chennai, and Thoothukudi) and one international facility in Tashkent, Uzbekistan. The company has built substantial distribution reach over its 30-year history, with presence in over 75 countries across Asia, Africa, Europe, and South America, and 342 distributors in India alone. The company's product portfolio spans consumer wellness, B2B formulations, and social impact food initiatives. According to EQMint analysis, mainboard listings generally offer better liquidity than SME counters, and the nutrition and healthcare segment has long-term structural growth potential, making this an attractive opportunity for investors seeking balanced risk-reward in the current selective IPO market.
